2018-2021 Hospital-Acquired Infection Control Global Market
Press
Release - 25 April 2018
Global
Research and Development News
--
.
.
Report
Description-
'
'
HAIs, which are also called nosocomial
infections, refer to a collection of conditions that a patient may
develop when being treated in hospitals or other healthcare
facilities. Modern healthcare settings use multiple devices to treat
patients. These can be breeding grounds for microorganisms, which can
have adverse effects on patient health. HAIs have caused a
significant cost burden on patients and healthcare facilities.
'
'
Technavios analysts forecast the global
hospital-acquired infection control market to grow at a CAGR of 4.81%
during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global hospital-acquired infection control market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of HAI products.
The market is divided into the following segments based on geography:
Americas
APAC
EMEA
Technavio's report, Global Hospital-Acquired Infection Control Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
AstraZeneca
GlaxoSmithKline
Merck
Pfizer
Other prominent vendors
3M
Abbott Laboratories
AbbVie
Advanced Sterilization Products
Alere
Bayer
BD
bioMrieux
Cepheid
Getinge Group
Hoffmann La-Roche
Synergy Health
Xenex
Market driver
Increasing innovative measures to prevent HAIs
For a full, detailed list, view our report
Market challenge
Emergence of antibiotic resistance
For a full, detailed list, view our report
Market trend
Emergence of innovative techniques to remove biofilms
For a full, detailed list, view our report
Key questions answered in this report
What will the market size be in 2021 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?
Covered in this report
The report covers the present scenario and the growth prospects of the global hospital-acquired infection control market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of HAI products.
The market is divided into the following segments based on geography:
Americas
APAC
EMEA
Technavio's report, Global Hospital-Acquired Infection Control Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
AstraZeneca
GlaxoSmithKline
Merck
Pfizer
Other prominent vendors
3M
Abbott Laboratories
AbbVie
Advanced Sterilization Products
Alere
Bayer
BD
bioMrieux
Cepheid
Getinge Group
Hoffmann La-Roche
Synergy Health
Xenex
Market driver
Increasing innovative measures to prevent HAIs
For a full, detailed list, view our report
Market challenge
Emergence of antibiotic resistance
For a full, detailed list, view our report
Market trend
Emergence of innovative techniques to remove biofilms
For a full, detailed list, view our report
Key questions answered in this report
What will the market size be in 2021 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?
– More
Clear Details get Table of Contents
https://www.researchmoz.us/global-hospital-acquired-infection-control-market-2017-2021-report.html/toc
'
'
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Research Methodology
PART 04: Introduction
Overview
PART 05: Market landscape
Overview
Market size and forecast
Five forces analysis
PART 06: Segmentation by infection type
Overview
CAUTIs
SSIs
CLABSIs
Respiratory infections
PART 07: Segmentation by end-user
Overview
Hospitals and ICUs
Outpatient care centers
LTCFs
Others
PART 08: Segmentation by geography
Overview
Americas
EMEA
APAC
PART 09: Decision framework
PART 10: Drivers and challenges
Market drivers
Market challenges
PART 11: Market trends
Emergence of innovative techniques to remove biofilms
Decrease in regulatory approvals of antibiotics
Focus on early diagnosis and preventive medicine
Cost burden of HAIs on patients and hospitals
PART 12: Vendor landscape
Competitive scenario
PART 13: Key vendor analysis
AstraZeneca
GlaxoSmithKline
Merck
Pfizer
PART 02: Scope of the report
PART 03: Research Methodology
PART 04: Introduction
Overview
PART 05: Market landscape
Overview
Market size and forecast
Five forces analysis
PART 06: Segmentation by infection type
Overview
CAUTIs
SSIs
CLABSIs
Respiratory infections
PART 07: Segmentation by end-user
Overview
Hospitals and ICUs
Outpatient care centers
LTCFs
Others
PART 08: Segmentation by geography
Overview
Americas
EMEA
APAC
PART 09: Decision framework
PART 10: Drivers and challenges
Market drivers
Market challenges
PART 11: Market trends
Emergence of innovative techniques to remove biofilms
Decrease in regulatory approvals of antibiotics
Focus on early diagnosis and preventive medicine
Cost burden of HAIs on patients and hospitals
PART 12: Vendor landscape
Competitive scenario
PART 13: Key vendor analysis
AstraZeneca
GlaxoSmithKline
Merck
Pfizer
Continue.....
Comments
Post a Comment